Aisa Pharma, Inc

AVEO Oncology is a Boston-based biopharmaceutical company dedicated to improving the lives of cancer patients through innovative medical solutions. As a subsidiary of LG Chem, the company focuses on developing and delivering effective treatments that address the unique challenges faced by individuals battling cancer. Committed to scientific advancement, AVEO's portfolio includes several promising therapies, such as FOTIVDA, Ficlatuzumab, and AV-380. The company's mission is driven by a passion for enhancing the quality of life for those affected by cancer, underscoring their focus on patient-centered care. Generated from the website

Alexion Pharmaceuticals is engaged in the discovery and development of therapeutic products aimed at treating patients with an array of diseases, including hematologic and cardiovascular disorders, autoimmune diseases and cancer. Alexion's two primary product candidates, pexelizumab and eculizumab, are currently undergoing evaluation in several clinical development programs with the Federal Drug Administration. Alexion is engaged in discovering and developing a pipeline of additional antibody therapeutics targeting severe unmet medical needs, through its wholly owned subsidiary, Alexion Antibody Technologies. During the fiscal year ended July 31, 2005, eculizumab was in Phase III clinical development for treatment of paroxysmal nocturnal hemoglobinuria , a chronic hematologic disease, and pexelizumab was in clinical development for two acute cardiac indications. Alexion is also pursuing additional potential indications for eculizumab and has other product candidates in earlier stages of development. Alexion Pharmaceuticals is based in Cheshire, Conn.

Visterra, Inc. is a biotechnology company based in Waltham, MA, dedicated to bringing better biologics to life. With a strong leadership team and a focus on innovative research, Visterra aims to develop groundbreaking therapies for various medical conditions. Through their comprehensive approach and extensive pipeline of programs, including VIS649 Sibeprenlimab, VIS171, and VIS513, Visterra is committed to advancing the field of biotechnology and improving patient outcomes. Their dedication to clinical trials, particularly in the area of IgA Nephropathy, showcases their commitment to finding effective treatments for challenging diseases.Generated from the website